Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer

Inclusion Criteria: * Signed informed consent * Histologically confirmed colorectal cancer * Age 18-70 years old * Advanced colorectal cancer patients, first-line or second-line treatment, the adjuvant treatment including the oxaliplatin or/and 5FU should be finished six months before * Have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. * ECOG 0-1 * Life expectancy of more than 3 months. * Normal laboratory values: hemoglobin \> 90g/dl, neutrophils \> 1.5×10\^9/L, platelets \> 100×10\^9/L, serum creatinine \< 1.5×upper limit of normal (ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN, AKP \< 4×ULN Exclusion Criteria: * Pregnant or lactating patients * Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety * Active or uncontrolled infection * Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure * Patients could not swallow the tablets * Concomitant with brain metastases